Shattuck Labs Inc
NASDAQ:STTK

Watchlist Manager
Shattuck Labs Inc Logo
Shattuck Labs Inc
NASDAQ:STTK
Watchlist
Price: 1.005 USD -0.5% Market Closed
Market Cap: 48m USD
Have any thoughts about
Shattuck Labs Inc?
Write Note

Shattuck Labs Inc
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shattuck Labs Inc
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
Shattuck Labs Inc
NASDAQ:STTK
Other Equity
$4k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Equity
-$2.3B
CAGR 3-Years
10%
CAGR 5-Years
2%
CAGR 10-Years
-10%
Gilead Sciences Inc
NASDAQ:GILD
Other Equity
$18.4B
CAGR 3-Years
526%
CAGR 5-Years
175%
CAGR 10-Years
61%
Amgen Inc
NASDAQ:AMGN
Other Equity
-$336m
CAGR 3-Years
25%
CAGR 5-Years
6%
CAGR 10-Years
-12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Equity
-$22.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Equity
$60.2m
CAGR 3-Years
82%
CAGR 5-Years
29%
CAGR 10-Years
8%
No Stocks Found

Shattuck Labs Inc
Glance View

Market Cap
48m USD
Industry
Biotechnology

Shattuck Labs, Inc. engages in the research and development of Agonist Redirected Checkpoint (ARC) platform. The company is headquartered in Austin, Texas and currently employs 85 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of dual-sided fusion proteins. The firm has created an approach to immune modulation by designing biologics with structural characteristics. Compounds derived from its Agonist Redirected Checkpoint (ARC) platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the cluster of differentiation 47/signal regulatory protein alpha (CD47/SIRPa) checkpoint interaction to restore an anti-tumor immune response and to activate the cluster of differentiation 40 (CD40) costimulatory receptor to bolster an immune response. The firm's second product candidate, SL-279252, is designed to simultaneously inhibit the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction and activate the OX40 receptor.

STTK Intrinsic Value
1.148 USD
Undervaluation 12%
Intrinsic Value
Price

See Also

What is Shattuck Labs Inc's Other Equity?
Other Equity
4k USD

Based on the financial report for Dec 31, 2023, Shattuck Labs Inc's Other Equity amounts to 4k USD.

Back to Top